Stephen R D Johnston
Overview
Explore the profile of Stephen R D Johnston including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
97
Citations
2945
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garcia-Murillas I, Cutts R, Walsh-Crestani G, Phillips E, Hrebien S, Dunne K, et al.
Breast Cancer Res Treat
. 2024 Oct;
209(3):493-502.
PMID: 39424680
Purpose: Detection of molecular residual disease (MRD) allows for the identification of breast cancer patients at high-risk of recurrence, with the potential that early initiation of treatment at early stages...
2.
Johnston S, Rugo H, Tolaney S, Munoz Fernandez M, Wei R, Martin M
Future Oncol
. 2024 Jul;
20(28):2037-2048.
PMID: 39023253
What Is This Summary About?: This article summarizes the most recent results of the monarchE study. This study was completed in participants with a type of breast cancer called HR+,...
3.
Goetz M, Cicin I, Testa L, Tolaney S, Huober J, Guarneri V, et al.
NPJ Breast Cancer
. 2024 Apr;
10(1):34.
PMID: 38671001
In monarchE, adjuvant abemaciclib significantly improved invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS), with sustained benefit beyond the 2-year treatment period. Abemaciclib dose reductions were allowed to proactively...
4.
Tolaney S, Guarneri V, Seo J, Cruz J, Abreu M, Takahashi M, et al.
Eur J Cancer
. 2024 Jan;
199:113555.
PMID: 38244363
Background: In monarchE, abemaciclib demonstrated a sustained benefit in invasive disease-free survival and a tolerable safety profile at 42-months median follow-up. With no expected disease-related symptoms, therapies in the adjuvant...
5.
Pegram M, Jackisch C, Johnston S
NPJ Breast Cancer
. 2023 May;
9(1):45.
PMID: 37258523
The human epidermal growth factor receptor 2 (HER2) is overexpressed in 13-22% of breast cancers (BC). Approximately 60-70% of HER2+ BC co-express hormone receptors (HRs). HR/HER2 co-expression modulates response to...
6.
Lother D, Robert M, Elwood E, Smith S, Tunariu N, Johnston S, et al.
Cancer Imaging
. 2023 May;
23(1):53.
PMID: 37254225
Background: Breast cancer is the most frequent cancer in women and remains the second leading cause of death in Western countries. It represents a heterogeneous group of diseases with diverse...
7.
Johnston S, Tolaney S, OShaughnessy J, Rastogi P, Harbeck N, Martin M
Lancet Oncol
. 2023 May;
24(6):e238.
PMID: 37146620
No abstract available.
8.
9.
Paluch-Shimon S, Neven P, Huober J, Cicin I, Goetz M, Shimizu C, et al.
Ther Adv Med Oncol
. 2023 Feb;
15:17588359231151840.
PMID: 36756142
Background: Abemaciclib is the first and only cyclin-dependent kinases 4 and 6 inhibitor approved for adjuvant treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, and...
10.